Nonalcoholic fatty liver disease (NAFLD) is the most common liver pathology in the developed world. Nonalcoholic fatty liver disease is associated with a higher risk of cardiovascular disease. We investigated the impact of ranolazine on liver tests in patients with NAFLD and coronary artery disease (CAD). Patients who had established CAD and NAFLD (as assessed by raised serum transaminase activity, sonographic criteria, and the absence of any other obvious liver disease) were allocated to “on ranolazine” (n = 40) or “not on ranolazine” (n = 35) groups. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured in all patients at baseline and at the end of the study. After 6 months of ranolazine treatment, both ALT and AST activities were significantly lower in patients in the “on ranolazine” group compared with “not on ranolazine” patients (change from baseline: ALT, −11.0 ± 1.7 IU/L, P < .001; AST, −5.2 ± 1.9 IU/L, P =.009). In conclusion, the present study showed that treatment with ranolazine for 6 months led to a significant reduction in the activities of both serum aminotransferases in patients with stable CAD and NAFLD.

Objectives: Thrombus by the activated platelets and reduced blood flow of myocardium as a result of the thrombus lies under the pathophysiology of acute myocardial infarction (MI). Mean platelet volume (MPV) is known to increase by the activation and rapid turnover of the platelets. This parameter has been shown to increase in acute MI and high levels are associated with poor prognosis. Trials comparing the MPV in ST elevated and non-ST elevated myocardial infarction (MI) patients are so rare in the literature. We aimed to search for the difference in MPV in these 2 types of acute MI. Materials and Methods: We retrospectively searched for the patients followed up because of acute MI in our coronary intensive care unit. MPV was routinely worked up from the admission complete blood count analysis. Patients were compared in two groups as ST elevation MI and non-ST elevation MI. Results: As a result, 356 elligible patients were included in our trial (203 were non-ST elevation patients, 153 were ST elevation patients). Mean patient age was 63 and 29% were female. MPV in non-ST elevation group was significantly higher than ST elevation MI group (10.5±1.2 vs 10.1±1.2, p=0.001).

No abstract